FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Previous Screen

Betaxolol Hydrochloride Ophthalmic Suspension
Status: Discontinuation
»Therapeutic Categories: Ophthalmology

Expand all

Novartis Pharmaceuticals Corporation (New 07/02/2024)

Company Contact Information:
888-669-6682

Presentation	Posting Date	Related Information
Betoptic S, Ophthalmic Suspension, 2.8 mg/1 mL (NDC 0078-0729-10)	07/02/2024	Novartis has made a business decision to permanently discontinue BETOPTIC S® (betaxolol hydrochloride ophthalmic suspension), 0.25% as base. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.
Betoptic S, Ophthalmic Suspension, 2.8 mg/1 mL (NDC 0078-0729-15)	07/02/2024	Novartis has made a business decision to permanently discontinue BETOPTIC S® (betaxolol hydrochloride ophthalmic suspension), 0.25% as base. Discontinuation of the product is not due to manufacturing, product quality, safety, or efficacy concerns.